Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$1.22
-1.6%
$1.34
$1.01
$8.08
$33.03M0.311.28 million shs561,068 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-4.62%+0.81%+13.76%-17.33%-18.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$1.22
-1.6%
$1.34
$1.01
$8.08
$33.03M0.311.28 million shs561,068 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-4.62%+0.81%+13.76%-17.33%-18.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
2.25
Hold$11.00801.64% Upside

Current Analyst Ratings Breakdown

Latest BTAI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/20/2026
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
Reiterated RatingSell (E+)
4/2/2026
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
Lower Price TargetBuy$6.00 ➝ $5.00
3/17/2026
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
Initiated CoverageBuy$17.00
3/9/2026
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
UpgradeStrong SellHold
3/5/2026
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
Lower Price TargetBuy$10.00 ➝ $6.00
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$642K51.45N/AN/A($4.37) per share-0.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$69.90M-$6.71N/AN/AN/A-10,887.38%N/A-181.48%5/11/2026 (Estimated)

Latest BTAI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$0.5325N/AN/AN/A$0.39 millionN/A
3/27/2026Q4 2025
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$0.58-$0.58N/A$0.65$0.15 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/A
0.83
0.82

Institutional Ownership

CompanyInstitutional Ownership
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
30.68%

Insider Ownership

CompanyInsider Ownership
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
9027.08 million26.07 millionNo Data

Recent News About These Companies

FDA Accepts BioXcel sNDA for At-Home IGALMI Use

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioXcel Therapeutics stock logo

BioXcel Therapeutics NASDAQ:BTAI

$1.22 -0.02 (-1.61%)
Closing price 04:00 PM Eastern
Extended Trading
$1.22 0.00 (-0.41%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.